From: microRNA expression pattern as an ancillary prognostic signature for radiotherapy
Before radiation | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Screening set (n = 8) | Training set (n = 38) | |||||||||||||
Poor response | Response | P | Poor response | Response | P | |||||||||
N | Mean | SD | N | Mean | SD | N | Mean | SD | N | Mean | SD | |||
Typeb | ||||||||||||||
H&N | 2 | 2 | 1 | 8 | 17 | 0.69 | ||||||||
Colorectal | 2 | 2 | 5 | 8 | ||||||||||
Agea | 4 | 69.75 | 16.24 | 4 | 62 | 16.81 | 0.52 | 13 | 61.54 | 15.03 | 25 | 61.08 | 15.21 | 0.93 |
Sexb | ||||||||||||||
Female | 1 | 1 | 1 | 6 | 13 | 0.732 | ||||||||
Male | 3 | 3 | 7 | 12 | ||||||||||
Stageb | ||||||||||||||
I | 1 | 1 | 0.23 | 1 | 4 | 0.111 | ||||||||
II | 0 | 2 | 0 | 6 | ||||||||||
III | 3 | 1 | 4 | 8 | ||||||||||
IV | 0 | 0 | 8 | 7 | ||||||||||
Total dosagea (Gy) | 3 | 63.87 | 11.68 | 4 | 60.25 | 11.37 | 0.69 | 13 | 66.18 | 7.58 | 24 | 63.61 | 9.29 | 0.398 |
Chemotherapyb | 4 | 4 | 1 | 13 | 25 | 0.728 |
Before radiation | |||||||
---|---|---|---|---|---|---|---|
Testing (n = 24) | |||||||
Poor response | Response | P | |||||
N | Mean | SD | N | Mean | SD | ||
Typeb | |||||||
H&N | 1 | 10 | 0.902 | ||||
Colorectal | 1 | 12 | |||||
Agea | 2 | 69.5 | 9.19 | 22 | 54.45 | 11.99 | 0.1 |
Sexb | |||||||
Female | 2 | 15 | 0.343 | ||||
Male | 0 | 7 | |||||
Stageb | |||||||
I | 0 | 3 | 0.081 | ||||
II | 0 | 6 | |||||
III | 0 | 8 | |||||
IV | 2 | 5 | |||||
Total dosagea (Gy) | 2 | 60.2 | 13.86 | 22 | 58.03 | 14.7 | 0.843 |
Chemotherapyb | 2 | 22 | 0.577 |
After radiation | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Screening set (n = 7) | Training set (n = 31) | |||||||||||||
Poor response | Response | P | Poor response | Response | P | |||||||||
N | Mean | SD | N | Mean | SD | N | Mean | SD | N | Mean | SD | |||
Typeb | ||||||||||||||
H&N | 2 | 2 | 0.66 | 7 | 15 | 0.94 | ||||||||
Colorectal | 1 | 2 | 3 | 6 | ||||||||||
Agea | 3 | 62.67 | 9.71 | 4 | 62 | 16.81 | 0.95 | 10 | 58.6 | 13.23 | 21 | 60.29 | 14.73 | 0.75 |
Sexb | ||||||||||||||
Female | 1 | 1 | 0.81 | 5 | 11 | 0.9 | ||||||||
Male | 2 | 3 | 5 | 10 | ||||||||||
Stageb | ||||||||||||||
I | 0 | 1 | 0.14 | 0 | 3 | 0.042* | ||||||||
II | 0 | 2 | 0 | 5 | ||||||||||
III | 3 | 1 | 2 | 7 | ||||||||||
IV | 0 | 0 | 8 | 6 | ||||||||||
Total dosagea (Gy) | 2 | 70.6 | 0.85 | 4 | 60.25 | 11.37 | 0.29 | 10 | 66.88 | 6.63 | 20 | 64.28 | 9.01 | 0.43 |
Chemotherapyb | 3 | 4 | 0.81 | 10 | 21 | 0.36 |
After radiation | |||||||
---|---|---|---|---|---|---|---|
Testing (n = 24) | |||||||
Poor response | Response | P | |||||
N | Mean | SD | N | Mean | SD | ||
Typeb | |||||||
H&N | 1 | 10 | 0.902 | ||||
Colorectal | 1 | 12 | |||||
Agea | 2 | 69.5 | 9.19 | 22 | 54.45 | 11.99 | 0.1 |
Sexb | |||||||
Female | 2 | 15 | 0.343 | ||||
Male | 0 | 7 | |||||
Stageb | |||||||
I | 0 | 3 | 0.081 | ||||
II | 0 | 6 | |||||
III | 0 | 8 | |||||
IV | 2 | 5 | |||||
Total dosagea (Gy) | 2 | 60.2 | 13.86 | 22 | 58.03 | 14.7 | 0.843 |
Chemotherapyb | 2 | 22 | 0.577 |